Oasmia

Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Read more
Rights issue 2019

Release

Q&A regarding Rights issue in Swedish

Press releases

November 18, 2019
Oasmia invites to investor meetings in connection to the rights issue
November 11, 2019 Regulatory press release
Oasmia resolves on a rights issue of approximately SEK 399 million
November 6, 2019 Regulatory press release
Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019

All press releases

Financial reports

Calendar

December 30, 2019 Interim Report May – October 2019
March 27, 2020 Interim Report May 2019 – January 2020
June 18, 2020 Year-end Report May 2019 – April 2020

The Share

Follow the share

We uses cookies in order to optimize your use of our website. Read more about cookies.

OK